{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:15Z","timestamp":1786980495126,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"medical practical technology tracking project of hebei province","award":["GZ2020010"],"award-info":[{"award-number":["GZ2020010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10072-021-05609-0","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T17:03:44Z","timestamp":1632848624000},"page":"2651-2658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors"],"prefix":"10.1007","volume":"43","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1692-8957","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"issue":"2","key":"5609_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"key":"5609_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10072-017-3027-1","volume":"38","author":"D Franciotta","year":"2017","unstructured":"Franciotta D, Gastaldi M, Sala A et al (2017) Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci 38:231\u2013236","journal-title":"Neurol Sci"},{"issue":"9","key":"5609_CR3","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s10072-020-04393-7","volume":"41","author":"N Rezaeimanesh","year":"2020","unstructured":"Rezaeimanesh N, Sahraian MA, Moghadasi AN et al (2020) Epidemiology of neuromyelitis optica spectrum disorder in Tehran, Iran: the prevalence, baseline characteristics, and clinical aspects. Neurol Sci 41(9):2647\u20132648","journal-title":"Neurol Sci"},{"issue":"6","key":"5609_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","volume":"89","author":"M Mori","year":"2018","unstructured":"Mori M, Kuwabara S, Paul F (2018) Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 89(6):555\u2013556","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"5609_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/14737175.2019.1648210","volume":"19","author":"A Bruscolini","year":"2019","unstructured":"Bruscolini A, La Cava M, Mallone F et al (2019) Controversies in the management of neuromyelitis optica spectrum disorder. Expert Rev Neurother 19(11):1127\u20131133","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"5609_CR6","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","volume":"2","author":"A Zekeridou","year":"2015","unstructured":"Zekeridou A, Lennon VA (2015) Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2(4):e110","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5609_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-2094-5-22","volume":"5","author":"DJ Graber","year":"2008","unstructured":"Graber DJ, Levy M, Kerr D, Wade WF (2008) Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 5:22","journal-title":"J Neuroinflammation"},{"issue":"3","key":"5609_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/WCO.0000000000000828","volume":"33","author":"K Fujihara","year":"2020","unstructured":"Fujihara K, Cook LJ (2020) Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. Curr Opin Neurol 33(3):300\u2013308","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"5609_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10072-020-04828-1","volume":"42","author":"A Marchionatti","year":"2021","unstructured":"Marchionatti A, Woodhall M, Waters PJ et al (2021) Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice. Neurol Sci 42(1):73\u201380","journal-title":"Neurol Sci"},{"issue":"4","key":"5609_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s10072-020-04892-7","volume":"42","author":"GT Maniscalco","year":"2021","unstructured":"Maniscalco GT, Allegorico L, Alfieri G et al (2021) Anti-MOG-associated demyelinating disorders: two sides of the same coin. Neurol Sci 42(4):1531\u20131534","journal-title":"Neurol Sci"},{"issue":"4","key":"5609_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/ene.14654","volume":"28","author":"J ZhangBao","year":"2021","unstructured":"ZhangBao J, Huang W, Zhou L et al (2021) Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: a comparative study in Chinese Han patients. Eur J Neurol 28(4):1308\u20131315","journal-title":"Eur J Neurol"},{"issue":"9","key":"5609_CR12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","volume":"69","author":"MA Mealy","year":"2012","unstructured":"Mealy MA, Wingerchuk DM, Greenberg BM et al (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69(9):1176\u20131180","journal-title":"Arch Neurol"},{"issue":"8","key":"5609_CR13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8):1019\u20131032","journal-title":"Eur J Neurol"},{"issue":"3","key":"5609_CR14","first-page":"155","volume":"23","author":"Neuroimmunology branch of Chinese Society for Immunology","year":"2016","unstructured":"Neuroimmunology branch of Chinese Society for Immunology (2016) Diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) in China. Chin J Neuroimmunol & Neurol 23(3):155\u2013166","journal-title":"Chin J Neuroimmunol & Neurol"},{"issue":"5","key":"5609_CR15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310\u20131323","journal-title":"Brain"},{"key":"5609_CR16","doi-asserted-by":"crossref","unstructured":"Shi Z, Du Q, Chen H et al (2019) Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol. 2020;267(4):913\u2013924","DOI":"10.1007\/s00415-019-09649-7"},{"key":"5609_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","volume":"28","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Mossburg SE, Kim SH et al (2019) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 28:64\u201368","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"5609_CR18","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V et al (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264(9):2003\u20132009","journal-title":"J Neurol"},{"issue":"7","key":"5609_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","volume":"22","author":"W Qiu","year":"2015","unstructured":"Qiu W, Kermode AG, Li R et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178\u20131182","journal-title":"J Clin Neurosci"},{"issue":"7","key":"5609_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659\u2013666","journal-title":"Neurology"},{"issue":"8","key":"5609_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/1352458518776584","volume":"25","author":"DB Bichuetti","year":"2019","unstructured":"Bichuetti DB, Perin M, Souza NA et al (2019) Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler 25(8):1150\u20131161","journal-title":"Mult Scler"},{"key":"5609_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","volume":"33","author":"AI Espiritu","year":"2019","unstructured":"Espiritu AI, Pasco P (2019) Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 33:22\u201332","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"5609_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","volume":"18","author":"Y Jiao","year":"2018","unstructured":"Jiao Y, Cui L, Zhang W et al (2018) Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurol 18(1):47","journal-title":"BMC Neurol"},{"key":"5609_CR24","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","volume":"9","author":"Q Huang","year":"2018","unstructured":"Huang Q, Wang J, Zhou Y et al (2018) Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol 9:2066","journal-title":"Front Immunol"},{"issue":"1","key":"5609_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 19(1):36","journal-title":"BMC Neurol"},{"key":"5609_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","volume":"385","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang CJ, Wang BJ et al (2018) Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 385:192\u2013197","journal-title":"J Neurol Sci"},{"issue":"03","key":"5609_CR27","first-page":"309","volume":"27","author":"H Yu","year":"2019","unstructured":"Yu H, Chen XJ, Yu X et al (2019) Efficacy and safety of reduced dosage of rituximab in Chinese patients with NMOSD. Chin J Clin Neurosci 27(03):309\u2013312","journal-title":"Chin J Clin Neurosci"},{"key":"5609_CR28","doi-asserted-by":"crossref","unstructured":"Poupart J, Giovannelli J, Deschamps R et al (2020) Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645\u2013e1656.","DOI":"10.1212\/WNL.0000000000009245"},{"key":"5609_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","volume":"35","author":"W Huang","year":"2019","unstructured":"Huang W, Wang L, Zhang B et al (2019) Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord 35:246\u2013252","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"5609_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","volume":"39","author":"H Chen","year":"2016","unstructured":"Chen H, Zhang Y, Shi Z et al (2016) The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol 39(2):81\u201387","journal-title":"Clin Neuropharmacol"},{"key":"5609_CR31","doi-asserted-by":"publisher","first-page":"101868","DOI":"10.1016\/j.msard.2019.101868","volume":"38","author":"A Kunchok","year":"2019","unstructured":"Kunchok A, Malpas C, Nytrova P et al (2019) Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 38:101868","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"5609_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann JP, Krumbholz M, Friede T et al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 88(8):639\u2013647","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"22","key":"5609_CR33","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"SH Kim","year":"2018","unstructured":"Kim SH, Mealy MA, Levy M et al (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91(22):e2089\u2013e2099","journal-title":"Neurology"},{"issue":"Pt 6","key":"5609_CR34","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135(Pt 6):1834\u20131849","journal-title":"Brain"},{"key":"5609_CR35","doi-asserted-by":"crossref","unstructured":"Sepulveda M, Delgado-Garc\u00eda G, Blanco Y et al (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e607.","DOI":"10.1212\/NXI.0000000000000607"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05609-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T02:08:42Z","timestamp":1647050922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5609"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05609-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}